Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-47339
Rev Assoc Med Bras (1992) 2019 Jul 22;656:893-901. doi: 10.1590/1806-9282.65.6.893.
Show Gene links Show Anatomy links

The role of Survivin as a biomarker and potential prognostic factor for breast cancer.

Veiga GLD , Silva RDMD , Pereira EC , Azzalis LA , Alves BDCA , Gehrke FS , Gascón TM , Fonseca FLA .


???displayArticle.abstract???
Breast cancer (BC) is one of the primary health problems worldwide. As the most common cancer in women in the world and in Brasil, behind only non-melanoma skin cancer, this neoplasm corresponds to approximately 28% of new cases per year in the country. BC also affects men, although the incidence corresponds to only 1% of total cases. Currently, most of the chemotherapeutic agents used in BC treatment are extremely toxic and cause long-term side effects. There is also a need to obtain earlier diagnoses, more accurate prognoses and make new therapies available that are more selective and effective in order to improve the current scenario. Therefore, this work sought to evaluate the importance of the biomarker survivin (Sur) in relation to BC, through the detailing of the role of Sur as a biomarker, the correlation between this protein and the prognosis of BC patients, and a summary of therapeutic strategies that target Sur for the development of new anticancer therapies.

???displayArticle.pubmedLink??? 31340322
???displayArticle.link??? Rev Assoc Med Bras (1992)


Genes referenced: birc5